Evidence map›Paper›PMID 34962453›Full record

ArticlePharmaceutical biology2022

Mechanism of Elian granules in the treatment of precancerous lesions of gastric cancer in rats through the MAPK signalling pathway based on network pharmacology.

Zhirong Yi, Qingling Jia, Yili Lin, Yujiao Wang, Jun Cong, Zhijian Gu, Jianghong Ling, Gan Cai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Zhirong YiThe First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, People's Republic of China.
Qingling JiaShuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Yili LinThe First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, People's Republic of China.
Yujiao WangShuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Jun CongShuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Zhijian GuShuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Jianghong LingThe First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, People's Republic of China.
Gan CaiShuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
First Affiliated Hospital of GuangXi Medical University · CNShanghai University of Traditional Chinese Medicine · CNShuguang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextElian Granules have been applied in the treatment of precancerous lesions of gastric cancer (PLGC) and achieved good results. However, its exact mechanism remains unclear.

objectivesTo explore the mechanism of Elian granules in treating PLGC through the mitogen-activated protein kinase (MAPK) signalling pathway based on network pharmacology. MATERIALS AND

methodsThrough network pharmacological methods, the targets of the active component of Elian granules against PLGC were obtained. Subsequently, Specific Pathogen Free (SPF) male Sprague Dawley (SD) rats were randomly divided into normal, model, and Elian granule groups. The

results394 and 4,395 targets were identified in Elian granules and PLGC, respectively. The 190 common targets were mainly enriched in MAPK signalling pathways. The gastric mucosal epithelium was still intact, the glands were arranged regularly, and no goblet cells or apparent inflammatory cell infiltration were observed in the Elian granule group. The expression of p-JNK and p-p38 protein of the Elian granule group (0.83 ± 0.08; 1.18 ± 0.40) was significantly higher than the model group (0.27 ± 0.14; 0.63 ± 0.14) ( DISCUSSION AND

conclusionsElian granules may play a critical role in the treatment of rat PLGC by up-regulating the expression of p-JNK and p-p38 proteins in the MAPK signalling pathway, thus providing a scientific basis for clinical application.

Indexed as

AnimalsDisease Models, AnimalDrugs, Chinese HerbalJNK Mitogen-Activated Protein KinasesMaleMAP Kinase Signaling SystemMethylnitronitrosoguanidineNetwork Pharmacologyp38 Mitogen-Activated Protein KinasesPrecancerous ConditionsRatsRats, Sprague-DawleyStomach NeoplasmsUp-RegulationDrugs, Chinese HerbalJNK Mitogen-Activated Protein KinasesMethylnitronitrosoguanidinep38 Mitogen-Activated Protein Kinasesbioinformation technologybiological network analysisChinese medicine formuladigestive diseasemolecular mechanism

Identifiers

PMID34962453
PMCPMC8725869
OpenAlexW4200098211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.